Braveheart Bio closed a $185 million financing to advance a small‑molecule candidate for obstructive hypertrophic cardiomyopathy toward registration‑enabling studies, positioning it as a potential challenger to Bristol Myers Squibb’s Camzyos. Investors including leading life‑science funds backed the round as Braveheart claims its molecule may offer safety advantages and plans global Phase 3 work. The drug was licensed from Jiangsu Hengrui, underscoring the growing pipeline flows from major Chinese developers into U.S. startups. The raise signals sustained investor appetite for cardiovascular assets that can address large, underserved indications.